Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103662 · ClinicalTrials.gov registry record · Phase 3
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 302
- Enrollment target
NCT00103662: Completed Phase 3 study, sponsored by Genzyme, a Sanofi Company.
NCT00103662 is a Phase 3 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 302 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00103662, a Phase 3 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 302 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in multiple myeloma patients for autologous transplantation.
Primary Outcome
Proportion of participants achieving a target of ≥ 6\*10\^6 CD34+ cells/kg in 2 or fewer days of apheresis. Central lab data were taken from Days 5 to 6 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 2 apheresis days.
Interventions
- DRUG Granulocyte colony-stimulating factor plus plerixafor
- DRUG Granulocyte colony-stimulating factor plus placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
What the finished NCT00103662 record still lists
NCT00103662 is an interventional study that assigns participants to a tested intervention. The registered 302 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 2 interventions - of which Granulocyte colony-stimulating factor plus plerixafor is the first listed.
NCT00103662 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00103662 about?
NCT00103662 is a clinical study titled "Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients". The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in multiple myeloma patients for autologous tran...
What is the current status of trial NCT00103662?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 302 participants. The study started on 2005-01. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00103662?
The interventions under investigation include: Granulocyte colony-stimulating factor plus plerixafor (DRUG), Granulocyte colony-stimulating factor plus placebo (DRUG).
Who is sponsoring clinical trial NCT00103662?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00103662's enrollment target sits among peer trials
302 1119th of 2000 higher than 880 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia